Researchers in Oxford are looking to recruit women who have painful osteoarthritis in joints of their hands, after resuming a study that was paused due to the COVID crisis.
Researchers at the University of Oxford are starting a new study to explore the effectiveness of the anti-tumour necrosis factor (anti-TNF) drug adalimumab as a treatment for patients with COVID-19 in the community, especially care homes. The AVID-CC trial, which will be conducted by Oxford Clinical Trials Research Unit (OCTRU), will enrol up to 750 patients from community care settings throughout the UK.
The statistical analysis and reporting of treatment effects in reports of randomised trials with a binary primary endpoint requires substantial improvement, suggests NDORMS research published in BMC Medicine.
A clinical trial to test whether Azithromycin, a commonly used antibiotic, can treat the symptoms of COVID-19 in outpatients has recruited its first patient.
Duncan Richards, Climax Professor of Clinical Therapeutics and Director of the Oxford Clinical Trials Research Unit (OCTRU) is interviewed about clinical trials and the challenges of running them in a pandemic.
In a new podcast Sallie Lamb, Head of the Rehabilitation Research Group at NDORMS talks about SARAH, the Strengthening and Stretching for Rheumatoid Arthritis of the Hand Trial.
![\"A](\"https://www.ndorms.ox.ac.uk/news/hope-e-study-resumes-recruitment-of-women-with-painful-osteoarthritis-in-the-hand/responsive_image?ratio=r16x9&scale=w760\")
\n \n \n\n\n